AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$CRMD

CorMedix Reaffirms 2026 Revenue Guidance of $325 Million–$345 Million and Reports $355 Million Cash Position

CorMedix (CRMD) reaffirmed 2026 revenue guidance of $325M–$345M and reported $355M in cash as of September 2026. CMS set a $8.32 add-on payment for DefenCath in Q1 2027, up from $2.37. The company expects fluctuations in 2027 but an average rate above $4.74. Q3 results are due November 12.

Original reporting
finance.yahoo.com
Published Nov 2, 2026, 1:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 2:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CorMedix Reaffirms 2026 Revenue Guidance of $325 Million–$345 Million and Reports $355 Million Cash Position — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CRMDBullishMed
01

Why it matters

The reaffirmed guidance and higher Medicare add‑on payment suggest stronger cash flow, likely supporting the stock price ahead of the upcoming Q3 earnings call.

02

Market read

The news provides fresh guidance and reimbursement data that can move CRMD and related healthcare stocks in the near term.

03

What to watch

Potential regulatory changes to Medicare rates beyond 2027 and competitive pressure from alternative dialysis therapies.

Relevance 7/10Novelty 8/10Timing: ahead of earnings on Nov 12

Background

CorMedix Therapeutics (NASDAQ:CRMD) provides dialysis infection‑prevention products. The company issued a business update on Nov 2, 2026, reaffirming its full‑year revenue outlook and reporting a cash balance of $355 M.

Company-level read

Ticker impact

$CRMDBullishHigh confidence
Context

CorMedix reaffirmed 2026 revenue guidance of $325‑$345 M and disclosed a new Medicare add‑on payment of $8.32 per dialysis session for Q1 2027.

Expected impact

likely upward pressure as the market prices in stronger cash flow and higher Medicare payments

Evidence & confidence

Guidance reaffirmation removes downside uncertainty, and the 3.5‑fold increase in Medicare payment is material for revenue.

Market effects

Sector

May lift peer dialysis and medical‑device stocks as higher Medicare rates improve sector profitability.

Regional

US healthcare sector could see modest gains in the short term.

Global

Limited to US‑listed biotech/healthcare investors.

Counterpoint

What could challenge this read

If the Q2‑Q4 2027 reimbursement rates fall as projected, the upside could be short‑lived.

Key entities

  • Company
    CorMedix Therapeutics

    NASDAQ‑listed biotech focused on dialysis infection‑prevention products.

  • Regulator
    Centers for Medicare & Medicaid Services (CMS)

    Set the new $8.32 per‑session add‑on payment for 2027.

Read at source← All news

StoryCMS sets $8.32 DefenCath add‑on for Q1 2027; CorMedix reaffirms 2026 revenue guidance and reports $355 M cash

Also covered by

2 outlets

Related articles

$CRMDMedAI 8/10

CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position Parsippany, NJ – November 2, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call ex

SEC EDGAR 8-K
$CRMDMed

CorMedix reports $355M cash, reaffirms 2026 revenue guidance

CorMedix (CRMD) reported $355M in cash as of September 30 and reaffirmed its 2026 revenue guidance of $325M-$345M. The CMS set a Q1 2027 Add-on payment for DefenCath at $8.32 per session, within the company's guided range. CorMedix expects the Add-on to decline in Q2 2027 but increase in Q3 and Q4, with the average rate exceeding 2x the current rate. The company plans to discuss financial results on November 12, 2026.

investing.com
$CRMDMed

A federal rule sets an $8.32 add-on payment per DefenCath dialysis session in Q1 2027.

CorMedix Therapeutics (CRMD) reported $355M in cash reserves as of Q3 2026 and reaffirmed its 2026 revenue guidance of $325M-$345M. CMS set an $8.32 Add-on payment per DefenCath dialysis session for Q1 2027, within CorMedix's guided range. The company expects the Add-on to decline in Q2 2027 but increase in later quarters, with an average rate exceeding 2x the current $2.37. CorMedix will discuss its Q3 financial results on November 12, 2026.

stocktitan.net
$CRMDMedAI 8/10

CorMedix Gains FDA Priority Review For REZZAYO's Potential New Indication

CorMedix (CRMD) and Mundipharma's REZZAYO (rezafungin) received FDA Priority Review for preventing invasive fungal diseases. The sNDA is based on the Phase 3 ReSPECT study, with a target action date in Q1 2027. REZZAYO is currently approved for treating candidemia and invasive candidiasis. If approved, CorMedix plans to start promotions in H2 2027. CRMD stock is up 0.55% in pre-market trading.

rttnews.com
$CRMDMedAI 8/10

CorMedix Wins Priority Review For REZZAYO SNDA In Fungal Disease Prevention

CorMedix (CRMD) announced the FDA accepted its sNDA for REZZAYO (rezafungin) to prevent fungal diseases, granting Priority Review. The application, submitted by partner Mundipharma, is based on a Phase 3 trial. The FDA set a target action date for Q1 2027. REZZAYO is currently approved for treating candidemia and invasive candidiasis in certain patients. The stock was up 0.55% in pre-market trading.

rttnews.com